Intensity Therapeutics
INTS
22 hedge funds and large institutions have $8.23M invested in Intensity Therapeutics in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
112% more capital inflows, than outflows
Capital inflows: $398K | Capital outflows: $188K
29% more funds holding
Funds holding: 17 → 22 (+5)
0.34% more ownership
Funds ownership: 11.91% → 12.25% (+0.34%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$172K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$126K |
| 3 |
HRT Financial
New York
|
+$72K |
| 4 |
BlackRock
New York
|
+$14.4K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$4.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sentinus LLC
Oak Brook,
Illinois
|
-$70.1K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$50.4K |
| 3 |
JP Morgan Chase
New York
|
-$40.2K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$21.2K |
| 5 |
Sapient Capital
Indianapolis,
Indiana
|
-$6.01K |
INTS Hedge Fund Activity: Q2 2024 in Review
22 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Intensity Therapeutics (INTS) for Q2 2024, worth a combined $8.23M — down 3.1% from $8.49M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new INTS positions and 1 closed out — a net gain of 5 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was William Blair & Company, opening a new position worth an estimated $172K. The largest seller was Sentinus LLC, cutting an estimated $70.1K.
- 22 institutional investors held Intensity Therapeutics (INTS) as of Q2 2024, up from 17 in Q1 2024.
- Funds reported $8.23M of Intensity Therapeutics stock for Q2 2024, down 3.1% quarter-over-quarter.
- 6 funds opened new Intensity Therapeutics positions in Q2 2024 and 1 closed out, a net change of +5 holders.
- The largest Intensity Therapeutics buyer in Q2 2024 was William Blair & Company, an estimated $172K added.
- The largest Intensity Therapeutics seller in Q2 2024 was Sentinus LLC, an estimated $70.1K sold.
Based on aggregated 13F filings for Q2 2024.